Agenus Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. Agenus is a clinical-stage biotechnology company developing cancer immunotherapies, including its lead botensilimab/balstilimab program, and vaccine adjuvants and cell therapies.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Total revenue | $24.3 million | $22.8 million | $72.5 million | $69.6 million |
| Operating loss | $46.3 million | $41.6 million | $155.3 million | $121.7 million |
| Net loss | $64.5 million | $56.7 million | $208.9 million | $156.6 million |
| Net loss attributable to Agenus common stockholders | $62.3 million | $54.3 million | $199.6 million | $149.1 million |
| Net loss per share, basic and diluted | $0.16 | $0.19 | $0.57 | $0.54 |
| Research and development expense | $51.4 million | $46.0 million | $167.8 million | $133.4 million |
| General and administrative expense | $18.9 million | $18.1 million | $57.6 million | $56.0 million |
| Interest expense, net | $18.6 million | $15.6 million | $53.7 million | $44.5 million |
- Revenue quality: Non-cash royalty revenue related to the sale of future GSK royalties was $20.4 million in Q3 and $61.5 million for the nine-month period. Total revenue also included collaboration and service revenue; revenue figures do not represent equivalent cash receipts to Agenus.
- Cash flow and liquidity: Cash and cash equivalents were $106.3 million at September 30, 2023, down from $178.7 million at December 31, 2022. Operating cash use was $183.8 million for the nine months, versus $128.0 million a year earlier. Financing activities provided $112.6 million, including $123.2 million of net proceeds from ATM share sales.
- Debt and other obligations: Debt principal was $13.4 million. The net liability related to sold future royalties and milestones was $265.6 million, of which $98.5 million was classified as current. Operating lease liabilities totaled approximately $65.7 million.
- Balance sheet: Total assets were $335.5 million and total stockholders’ deficit was $115.3 million. Accumulated deficit was $1.9 billion.
- Margins: The filing does not provide a clear, decision-useful gross margin measure for the business; Agenus reported an operating loss and is in clinical-stage development.
Material changes versus prior comparable periods
- Nine-month revenue increased 4% year over year, primarily reflecting higher non-cash royalty revenue, partly offset by lower research and development revenue and no 2023 royalty sales milestone revenue. The 2022 period included $25.3 million in royalty milestone revenue.
- Nine-month R&D expense rose 26%, primarily due to increased third-party services and other expenses, including costs associated with advancing antibody programs. G&A expense rose 3%.
- Nine-month net loss increased to $208.9 million from $156.6 million. Higher operating expenses and interest expense contributed; 2022 also included gains on asset sales and partial liability forgiveness that did not recur.
- Shares issued increased during 2023, including 71.6 million shares sold through the ATM for $123.2 million net proceeds. The company reported 381.5 million shares outstanding as of November 3, 2023.
Outlook, management commentary, and risks
- Going concern: Management said September 30 cash, together with an anticipated partnership milestone, was expected to meet liquidity needs for at least one year from issuance of the statements. However, the filing states that substantial doubt about the company’s ability to continue as a going concern exists until the milestone is achieved. The milestone depends on first-patient dosing in a trial then screening patients, expected by year-end 2023.
- Potential funding—not assured: Agenus was in discussions to sell two non-strategic assets for an estimated aggregate $65 million, expected to close in the first half of 2024, and in advanced discussions about structured financing for botensilimab/balstilimab and a corporate collaboration. These are prospective, not completed transactions.
- Cost and program changes: In August 2023, Agenus said it was prioritizing its lead asset, postponing all preclinical and other clinical programs, and reducing its workforce by approximately 25%. The CEO elected to receive salary and potential bonuses in stock rather than cash.
- Clinical and regulatory plans: The company reported October 2023 Phase 1 data for botensilimab plus balstilimab in 70 efficacy-evaluable refractory microsatellite-stable metastatic colorectal cancer patients without active liver metastases: 12-month overall survival was 74%, median overall survival had not been reached at median follow-up of 12.3 months, and confirmed response rate was 24%. Comparisons cited were to reported standard-of-care results, not a concurrent control arm. Agenus said it intended to file its first BLA for the combination in colorectal cancer in mid-2024; timing and success remain uncertain.
- Other risks and contingencies: Cash held by MiNK may not be freely available to Agenus. The company depends on partnerships, milestones, asset sales, financing, or equity issuance to fund continued development and has significant clinical-trial and regulatory execution risks. No material legal proceedings were reported. Management stated disclosure controls were effective and there was no material change in internal control over financial reporting during the quarter.
Investor verification priorities
- Verify whether and when the anticipated partnership milestone was achieved, its cash amount, and the resulting updated liquidity and going-concern assessment.
- Check whether the proposed asset sales, structured financing, or corporate collaboration closed, and review their proceeds, terms, and restrictions.
- Track operating cash use, cash runway, ATM share issuance, and dilution; distinguish cash royalty receipts paid to HCR from Agenus’s non-cash royalty revenue recognition.
- Review subsequent botensilimab/balstilimab trial results, enrollment and regulatory progress, and the basis for the planned mid-2024 BLA timeline.
- Assess the effects of the workforce reduction and program pauses on development timelines, spending, and the company’s ability to preserve its lead-program execution.